Table 2.

Comparison of NCCLS- and XTT-based MIC data for antifungal susceptibility testing of clinical isolates ofCandida and C. neoformans

Antifungal agentMIC (μg/ml) for isolate (no. tested) by method
C. albicans(29)C. glabrata (12)C. tropicalis (17)C. guilliermondii(6)C. parapsilosis(18)C. lusitaniae(11)C. krusei (5)C. neoformans (20)
NCCLSXTTNCCLSXTTNCCLSXTTNCCLSXTTNCCLSXTTNCCLSXTTNCCLSXTTNCCLSXTT
Amphotericin B0.25–4.00.25–4.00.5–20.5–20.5–20.5–20.25–10.5–10.125–20.25–10.125–0.50.06–0.51.0–2.00.5–2.00.5–20.25–2.0
Fluconazole0.125–>2560.25–>2568–2568–1280.25–>2560.25–>2562.0–16.02.0–321.0–640.5–322.0–8.02.0–8.032–12832–642.0–>2561.0–>256
Itraconazole0.125–>160.125–>160.5–>160.5–>160.06–>160.06–>160.25–40.125–40.125–10.06–0.50.06–10.06–10.125–160.125–160.125–>160.06–>16
Ketoconazole0.03–>160.015–160.5–4.00.5–80.015–160.015–160.125–20.125–40.125–0.50.03–0.1250.03–0.50.06–0.50.25–8.00.5–8.00.25–>160.125–>16
Flucytosine0.125–>640.125–>640.03–10.03–0.50.03–640.03–640.03–0.250.03–0.250.125–0.5<0.03–0.1250.03–>640.06–>642.0–8.01.0–8.00.25–0.50.125–1.0